June 4, 2018
FibroGen’s pamrevlumab+chemotherapy could be neoadjuvant treatment regimen for certain advanced pancreatic cancer
FibroGen, a biopharmaceutical company, on Monday said the results from the Phase 1/2 clinical trial, testing pamrevlumab in combination with…